Read the article here.
0 Comments
Read the article here.
In 2015, at the United Nations Climate Change Conference (COP21), 196 countries adopted the Paris Agreement to limit global warming to no more than 1.5 °C. This requires countries to cut emissions by at least 45% compared with 2010 levels, and reach net zero by 2050. However, the current commitments from this coalition of countries fall far short; based on current plans, rather than falling, emissions will increase by almost 30% by 2030. It's vital that companies, as well as governments, get behind the goal of net zero as soon as possible.
Read more at Pharma Sources. MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.
.https://www.nature.com/articles/d43747-024-00019-5 MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.
https://www.nature.com/articles/d43747-024-00019-5 Nanoparticles are small particles between 1 nm and 100 nm, and there is growing interest in nanotechnology in energy, electronics, materials science and biomedicine.
The global healthcare nanotechnology market was worth around $320 billion in 2023, and could be worth as much as $894 billion by 2032. Nanoparticles have potential in imaging, diagnostics, bio-implants and tissue engineering. One of their growing roles is in targeted and controlled drug delivery. Read more at Pharma Sources. Read the article here.
Read the article here.
The pharmaceutical market is growing fast. According to Statista, revenue in the global pharmaceuticals market is expected to reach US$1,156.00 billion in 2024, growing at an annual growth rate (CAGR) of 6.19% between 2024 and 2028. The largest market is oncology, predicted to be worth US$214.10 billion in 2024.
It’s also an industry that’s changing fast. Basic research is adding new approaches to treating specific diseases, and new technologies are allowing researchers to find new leads at lower risk of failure. Read more at Pharma Sources. |
Archives
July 2024
Categories |